首页|毫米波联合多西他赛加顺铂在非小细胞肺癌治疗中的效果分析

毫米波联合多西他赛加顺铂在非小细胞肺癌治疗中的效果分析

扫码查看
目的 分析毫米波联合多西他赛加顺铂在非小细胞肺癌(Non-small Cell Lung Cancer,NSCLC)治疗中的效果.方法 目的选取2021年7月—2023年7月金湖县人民医院收治的82例NSCLC患者为研究对象,以治疗方法不同分为对照组和研究组,每组41例.对照组使用多西他赛治疗,研究组使用毫米波联合多西他赛加顺铂治疗.比较两组症状缓解情况、肿瘤标志物水平、不良反应.结果 研究组症状缓解率(82.93%)高于对照组(63.41%),差异有统计学意义(χ2=3.976,P<0.05).研究组的肿瘤标志物水平低于对照组,差异有统计学意义(P均<0.05).两组不良反应发生率对比,差异无统计学意义(P>0.05).结论 毫米波联合多西他赛加顺铂在NSCLC治疗中能够发挥积极作用,不仅降低肿瘤标志物水平,还可缓解临床症状,且安全性较高.
Effect of Millimeter Wave Combined with Docetaxel Plus Cisplatin in the Treatment of Non-small Cell Lung Cancer
Objective To analyze the effect of millimeter wave combined with docetaxel plus cisplatin in the treatment of non-small cell lung cancer(NSCLC).Methods A total of 82 patients with NSCLC admitted to Jinhu County People's Hospital from July 2021 to July 2023 were purposefully selected as the study objects,and were divided into control group and study group by difference treatment,with 41 cases in each group.The control group was treated with docetaxel,and the study group was treated with millimeter wave combined with docetaxel and cisplatin.Symptom re-lief,tumor marker levels and adverse reactions were compared between the two groups.Results The symptom remis-sion rate of the study group(82.93%)was higher than that of the control group(63.41%),and the difference was statis-tically significant(χ2=3.976,P<0.05).The level of tumor markers in the study group was lower than that in the control group,and the difference was statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Millimeter wave combined with docetaxel and cis-platin can play a positive role in the treatment of NSCLC,not only reducing the level of tumor markers,but also allevi-ating clinical symptoms,with high safety.

Non-small cell lung cancerMillimeter waveDocetaxelCisplatinTumor markersAdverse reaction

闵潇莹、张焕明、蔡守兵

展开 >

金湖县人民医院肿瘤血液科,江苏 金湖 211600

非小细胞肺癌 毫米波 多西他赛 顺铂 肿瘤标志物 不良反应

2024

系统医学

系统医学

ISSN:
年,卷(期):2024.9(12)